http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 11 Aug 2026 16:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aquestive+Therapeutics%2C+++For%3A+Jun+30/26905820.html si-local-file:///var/storage/secattach/20260811/26905820.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aquestive+Therapeutics%2C+++For%3A+Jun+30/26905820.html Tue, 11 Aug 2026 16:11:00 -0400 AQST O.37573242 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aquestive+Therapeutics%2C+++For%3A+Jun+30/26905820.html si-local-file:///var/storage/secattach/20260811/26905820.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aquestive+Therapeutics%2C+++For%3A+Jun+30/26905820.html Tue, 11 Aug 2026 16:11:00 -0400 AQST O.37573242 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+11/26905658.html si-local-file:///var/storage/secattach/20260811/26905658.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+11/26905658.html Tue, 11 Aug 2026 16:07:00 -0400 AQST O.37573242 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+11/26905658.html si-local-file:///var/storage/secattach/20260811/26905658.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aquestive+Therapeutics%2C+++For%3A+Aug+11/26905658.html Tue, 11 Aug 2026 16:07:00 -0400 AQST O.37573242 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update+/26905402.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update+/26905402.html Tue, 11 Aug 2026 16:01:00 -0400 AQST http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update+/26905402.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update+/26905402.html Tue, 11 Aug 2026 16:01:00 -0400 AQST http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Press+Releases/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767 http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html <ul><li><em>Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film</em></li><li><em>Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026</em></li><li><em>Continues pre-launch medical affairs activities and payer engagement</em></li><li><em>On track to begin ex-U.S. filings of Anaphylm in Q4 2026</em></li><li><em>Company to host investor call on August 12, 2026, at 8:00 a.m. ET</em></li></ul> <p align="justify">WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (&quot;Aquestive&quot; or the &quot;Company&quot;), a pharmaceutical company advancing medicines to bring meaningful improvement to patients&apos; lives through innovative science and delivery technologies, today announced financial results for the http://www.streetinsider.com/Globe+Newswire/Aquestive+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905416.html Tue, 11 Aug 2026 16:01:00 -0400 A.02429381 A.03620480 A.06822034 A.13193403 AQST O.00183299 O.06200738 O.20026344 O.37573242 O.41197767